Add Yahoo as a preferred source to see more of our stories on Google. (The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday.

Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. Man found guilty after 1980 death of Mt. Hood Community College ...